Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allakos Inc. - Common Stock (NQ: ALLK )

1.200 -0.090 (-6.98%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 474,457
Open 1.280
Bid (Size) 1.200 (76)
Ask (Size) 1.300 (3)
Prev. Close 1.290
Today's Range 1.200 - 1.380
52wk Range 0.5350 - 3.360
Shares Outstanding 86,560,315
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga

Performance

YTD
-56.20%
-56.20%
1 Month
+32.32%
+32.32%
3 Month
+120.67%
+120.67%
6 Month
N/A
N/A
1 Year
-54.72%
-54.72%

More News

Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
ALLK Stock Earnings: Allakos Beats EPS for Q2 2024
Via InvestorPlace
ALLK Stock Earnings: Allakos Meets EPS for Q1 2024
Via InvestorPlace
ALLK Stock Earnings: Allakos Misses EPS for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
From Allakos Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
From Allakos Inc.
Via GlobeNewswire
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
From Allakos Inc.
Via GlobeNewswire
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
From Allakos Inc.
Via GlobeNewswire
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
From Allakos Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
3 Biotech Stocks to Dump Before They Go to Zero
Via InvestorPlace
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Allakos Inc.
Via GlobeNewswire
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
From Allakos Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
From Allakos Inc.
Via GlobeNewswire
Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Gold Down 1%; PNC Financial Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.